Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine
JCO Clinical Cancer Informatics · 2025
DOI: 10.1200/cci-24-00308 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2025. Verfasst von Nazmul Islam und 18 weiteren Autor:innen. Beteiligte Einrichtung: RefinedScience, Aurora, CO. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Azacitidine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE The objective of this study was to develop a flexible risk stratification strategy for AML that is specific for venetoclax plus azacitidine (ven/aza), addresses real-world data (RWD) issues, and is also adaptable to different use cases. METHODS A series of tunable risk models (RMs) were generated from a dynamic counterfactual machine learning (ML) strategy. These used a range of features from diagnostic AML samples and were tested using objective metrics on a single-institution cohort of 316 newly diagnosed patients treated with ven/aza. RM performance was tested using various model assumptions, data elements, and end points and with applications to an external AML real-world cohort (RWC). RESULTS Favorable, intermediate, and adverse risk groups were identified in a series of ML-based RMs using different assumptions, for genetic-only or genetic-plus-phenotypic data elements and with overall survival and event-free survival as end points. Most RMs demonstrated equitable patient distribution (approximately 20%-40% in each risk group), significant separation between risk strata (log-rank–based P values
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- RefinedScience, Aurora, CO.
- Department of Pathology, University of Colorado Anschutz Campus, Aurora, CO.
- Department of Medicine, University of Colorado Anschutz Campus, Aurora, CO.
- OncoVerity, Aurora, CO.
ORCID-Profile: Nazmul Islam, Justin L Dale, Jamie S Reuben, Karan Sapiah, James W Coates, Frank R Markson, William M Showers, Monica R Ransom, Ujjwal V Kulkarni, Craig T Jordan, Clayton A Smith
Zitieren
APA
Islam, N., Dale, J. L., Reuben, J. S., Sapiah, K., Coates, J. W., Markson, F. R., Zhang, J., Wu, L., Gasparetto, M., Stevens, B. M., Staggs, S. E., Showers, W. M., Ransom, M. R., Desai, J., Kulkarni, U. V., Engel, K. L., Jordan, C. T., Boyiadzis, M., & Smith, C. A. (2025). Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci-24-00308
Vancouver
Islam N, Dale JL, Reuben JS, Sapiah K, Coates JW, Markson FR, et al. Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine. JCO Clinical Cancer Informatics. 2025. doi:10.1200/cci-24-00308
BibTeX
@article{Islam2025,
author = {Islam, Nazmul and Dale, Justin L and Reuben, Jamie S and Sapiah, Karan and Coates, James W and Markson, Frank R and Zhang, Jingjing and Wu, Lezhou and Gasparetto, Maura and Stevens, Brett M and Staggs, Sarah E and Showers, William M and Ransom, Monica R and Desai, Jairav and Kulkarni, Ujjwal V and Engel, Krysta L and Jordan, Craig T and Boyiadzis, Michael and Smith, Clayton A},
title = {Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine},
journal = {JCO Clinical Cancer Informatics},
year = {2025},
doi = {10.1200/cci-24-00308}
}
EUVIMED